The influence of treatment, age at onset, and metabolic control on height in children and adolescents with type 1 diabetes-A SWEET collaborative study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10383545" target="_blank" >RIV/00216208:11130/18:10383545 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/18:10383545

Výsledek na webu

<a href="https://doi.org/10.1111/pedi.12751" target="_blank" >https://doi.org/10.1111/pedi.12751</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/pedi.12751" target="_blank" >10.1111/pedi.12751</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The influence of treatment, age at onset, and metabolic control on height in children and adolescents with type 1 diabetes-A SWEET collaborative study

Popis výsledku v původním jazyce

Objective To describe the association between height, demographics, and treatment in youths with type 1 diabetes participating in an international network for pediatric diabetes centers (SWEET). Methods Data were collected from 55 centers with documented patients&apos; height. All subjects below 20 years of age, diabetes duration &gt;1 year, and without celiac disease were included. World Health Organization growth charts were used to calculate height and body mass index z-scores. Multiple hierarchic regression models adjusting for known confounders were applied. Results Data on 22 941 subjects (51.8% male) were analyzed with a median and interquartile range for age 14.8 years (11.2, 17.6), diabetes duration 5.6 years (3.1, 8.9), and height z-score 0.34 (-0.37, 1.03). Children were taller in the youngest age groups: adjusted height z-scores of 0.31 (+/- 0.06) and 0.39 (+/- 0.06), respectively; with shorter diabetes duration (&lt;2 years: 0.36 [+/- 0.06]; 2-&lt;5 years: 0.34 [+/- 0.06]; &gt;= 5 years: 0.21 [+/- 0.06]) and if they were pump users: 0.35 +/- 0.05 vs 0.25 +/- 0.05 (&gt;three injections/day and 0.19 +/- 0.06 [0-3 injections daily]), respectively. High hemoglobin A1c (HbA1c) and low to normal weight were associated with a lower height z-score. Trends were identical in all models except for gender. No gender differences were found except in the final height model where females exhibited higher z-score than males. Conclusion For youths treated at centers offering modern diabetes management, major growth disturbances are virtually eliminated. For children with a young age at onset, high HbA1c, injections, and/or non-intensive diabetes, treatment still requires attention in order to attain normal growth.

Název v anglickém jazyce

The influence of treatment, age at onset, and metabolic control on height in children and adolescents with type 1 diabetes-A SWEET collaborative study

Popis výsledku anglicky

Objective To describe the association between height, demographics, and treatment in youths with type 1 diabetes participating in an international network for pediatric diabetes centers (SWEET). Methods Data were collected from 55 centers with documented patients&apos; height. All subjects below 20 years of age, diabetes duration &gt;1 year, and without celiac disease were included. World Health Organization growth charts were used to calculate height and body mass index z-scores. Multiple hierarchic regression models adjusting for known confounders were applied. Results Data on 22 941 subjects (51.8% male) were analyzed with a median and interquartile range for age 14.8 years (11.2, 17.6), diabetes duration 5.6 years (3.1, 8.9), and height z-score 0.34 (-0.37, 1.03). Children were taller in the youngest age groups: adjusted height z-scores of 0.31 (+/- 0.06) and 0.39 (+/- 0.06), respectively; with shorter diabetes duration (&lt;2 years: 0.36 [+/- 0.06]; 2-&lt;5 years: 0.34 [+/- 0.06]; &gt;= 5 years: 0.21 [+/- 0.06]) and if they were pump users: 0.35 +/- 0.05 vs 0.25 +/- 0.05 (&gt;three injections/day and 0.19 +/- 0.06 [0-3 injections daily]), respectively. High hemoglobin A1c (HbA1c) and low to normal weight were associated with a lower height z-score. Trends were identical in all models except for gender. No gender differences were found except in the final height model where females exhibited higher z-score than males. Conclusion For youths treated at centers offering modern diabetes management, major growth disturbances are virtually eliminated. For children with a young age at onset, high HbA1c, injections, and/or non-intensive diabetes, treatment still requires attention in order to attain normal growth.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pediatric Diabetes

ISSN

1399-543X

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

1441-1450

Kód UT WoS článku

000450682300013

EID výsledku v databázi Scopus

2-s2.0-85054572089